EMA Authorised: Plegridy (peginterferon beta-1a) — Biogen Netherlands B.V.

View source ↗

Summary

The EMA authorised Plegridy (peginterferon beta-1a) from Biogen Netherlands B.V. for the treatment of multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Plegridy (Peginterferon beta-1a)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis. MAH: Biogen Netherlands B.V.. Decision date: 11/12/2025